A rare seat on one of Asia's most consistently award-winning China long-biased platforms with over $1B USD AUM, deep fundamental process and on-the-ground Greater China research, and a multi-year track record of winning across China equity, long/short equity, and absolute return categories.

If you have conviction in China and want a platform that has kept compounding through the cycle, this is the seat.

The Seat:

1. Cover China Public Equities end-to-end idea generation, deep fundamental work, channel checks etc
2. Build and defend high-conviction long ideas directly to the PM
3. Sector coverage is flexible: the firm is open to strong analysts from any sector background but would prefer if you had experience in tech and consumer
4. Real ownership of names and exposure to portfolio construction conversations

Must-Haves:

1. Strong China public equities coverage in a hedge fund / long-only / sell-side research seat
2. buy-side PE/VC background covering China with a clear desire to move into public markets
3. Fluent in Mandarin
4. Top Academic Background from globally leading universities

Nice-to-Have:

1. Specific sector depth in TMT, consumer, healthcare, industrials, or financials

Prior experience integrating alternative data into a fundamental process

CFA, MBA, or relevant postgraduate qualification

For Passive Candidates:

You do not need to be actively looking to explore this. If you are in a good China-focused seat but feel under-leveraged on platform quality, PM access, or the calibre of the process around you, or if you are on the private side and have been thinking about the move into public equities, a short confidential conversation is worth your time. China-dedicated seats on platforms with this kind of multi-year award track record do not come up often.

If you or anyone else you know is interested, please contact Rhythy Yeung at

mailto:rhythy@darmaxglobal.com

or you can also reach me via WA at +852 5622 5422 for more